Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dolutegravir inhibits HIV-1 Env evolution in primary human cells.

AIDS (London, England) - 27 Mar 2015

Mesplède Thibault, Moïsi Daniela, Oliveira Maureen, Ibanescu Ilinca, Ohnona Frédéric, Brenner Bluma, Wainberg Mark A

Abstract excerpt

OBJECTIVE: In treatment-naive HIV-positive individuals, the integrase strand-transfer inhibitor dolutegravir (DTG) has not been associated with emergent drug-resistance mutations, neither against this drug nor against other antiretroviral drugs that were used in combination with it. This is in contrast to all other antiretroviral drugs tested so far, including the integrase strand-transfer inhibitors raltegravir...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to env Gene Products, Human Immunodeficiency Virus
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation Rate

Share to Oxazines

Share to Piperazines

Share to Pyridones

Share to Raltegravir Potassium

Share to Serial Passage

Source

Identifiers

PMID: 25849829
DOI: 10.1097/QAD.0000000000000606

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dolutegravir inhibits HIV-1 Env evolution in primary human cells.PMID 25849829Read ↗

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.Semantic proximity Read ↗

The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.Semantic proximity Read ↗

Dolutegravir resistance mutations: lessons from monotherapy studies.Semantic proximity Read ↗

Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance SubstitutionsSemantic proximity Read ↗

What if HIV were unable to develop resistance against a new therapeutic agent?Semantic proximity Read ↗

Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.Semantic proximity Read ↗

The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.Semantic proximity Read ↗

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug ResistanceSemantic proximity Read ↗

Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.Semantic proximity Read ↗

The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravirSemantic proximity Read ↗

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressureSemantic proximity Read ↗

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.